HDACi combination therapy with IDO1i remodels the tumor microenvironment and boosts antitumor efficacy in colorectal cancer with microsatellite stability
The combination of IDO1 and HDAC inhibitors represents a promising strategy for CRC treatment, and NP-I/P is a candidate for clinical trials.
Authors
- Yiquan Li (ORCID: https://orcid.org/0009-0007-0269-835X)
- Tianyun Lan
- Jiannan Ren (ORCID: https://orcid.org/0000-0003-1302-5007)
- Svetlana Ryabtseva (ORCID: https://orcid.org/0000-0001-9803-8709)
- Bo Wei (ORCID: https://orcid.org/0000-0001-5573-5715)
- Rongpu Liang (ORCID: https://orcid.org/0000-0002-5526-0753)
- He Huang (ORCID: https://orcid.org/0000-0002-2723-1621)
- Shengxin Huang (ORCID: https://orcid.org/0000-0001-8205-283X)
- Dongbing Ding (ORCID: https://orcid.org/0009-0005-2585-3784)
Institutions
- Sun Yat-sen University (CN)
- Institute of Physiology National Academy of Sciences of Belarus (BY)
- Third Affiliated Hospital of Sun Yat-sen University (CN)
Publication Details
- Journal
- Journal of Nanobiotechnology
- Published
- 2024-12-16
- DOI
- https://doi.org/10.1186/s12951-024-02936-0
- Citations
- 10
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 2.34
Funders
- Sun Yat-sen University
- Science and Technology Planning Project of Guangdong Province
- Basic and Applied Basic Research Foundation of Guangdong Province